A5034097209- Advanced Breast Cancer Therapies
- Chronic Lymphocytic Leukemia Research
- Cancer therapeutics and mechanisms
- Retinoids in leukemia and cellular processes
- Protein Degradation and Inhibitors
- Neuroendocrine Tumor Research Advances
- Phytochemistry and Biological Activities
- Insect Pest Control Strategies
- Immune Cell Function and Interaction
- Cytomegalovirus and herpesvirus research
- Immunotherapy and Immune Responses
- Essential Oils and Antimicrobial Activity
- Natural product bioactivities and synthesis
- Phytochemical Studies and Bioactivities
- Piperaceae Chemical and Biological Studies
- CAR-T cell therapy research
Huazhong University of Science and Technology
2010-2025
Anhui Medical University
2024-2025
Second Hospital of Anhui Medical University
2024-2025
Background Resistance to existing therapies is a major cause of treatment failure in patients with refractory and relapsed B-cell non-Hodgkin’s lymphoma (r/r B-NHL). Therapy-induced senescence (TIS) one the most important mechanisms drug resistance. Methods This study used single-cell RNA sequencing analyze doxorubicin-induced senescent B-NHL cells. C-C chemokine receptor 7 (CCR7) expression aggressive was assessed using immunohistochemistry flow cytometry. Lentiviral transfection target...
Differentiation therapy based on ATRA almost cured acute promyelocytic leukemia (APL). However, it is disappointing that not effective against other myeloid (AML) subtypes. Developing new and anti-AML therapies promote differentiation necessary. The CDK4/6-cyclin D pathway a key initiator of the G1-S phase transition, which determines cell fate. Herein, we investigated whether CDK4/6 inhibitor palbociclib would synergize with to in vitro vivo. Our findings revealed genes were aberrantly...
<div>Abstract<p>Differentiation therapy based on ATRA almost cured acute promyelocytic leukemia (APL). However, it is disappointing that not effective against other myeloid (AML) subtypes. Developing new and anti-AML therapies promote differentiation necessary. The CDK4/6-cyclin D pathway a key initiator of the G1–S phase transition, which determines cell fate. Herein, we investigated whether CDK4/6 inhibitor palbociclib would synergize with to <i>in vitro</i>...
<div>Abstract<p>Differentiation therapy based on ATRA almost cured acute promyelocytic leukemia (APL). However, it is disappointing that not effective against other myeloid (AML) subtypes. Developing new and anti-AML therapies promote differentiation necessary. The CDK4/6-cyclin D pathway a key initiator of the G1–S phase transition, which determines cell fate. Herein, we investigated whether CDK4/6 inhibitor palbociclib would synergize with to <i>in vitro</i>...
<p>Figure S3. Knockdown CDK4 and CDK6 via siRNA in HL-60 molm13 cells (A). The effect of palbociclib ATRA combination on cell cycle(B), proliferation (C), apoptosis (D). * Represent when it compares with the control group, P<0.05. # P<0.05.</p>
<p>Figure S2. The comparison of the expression CDK4/6-cyclin D pathway genes based on age (A) and risk stratification (B). Kaplan-Meier curve for CDK6 (C). calibration nomogram 1-year 2-year overall survival (D).</p>
<p>Figure S4. The effect of Palbociclib and ATRA combination on leukemia burden in vivo (A). Volcano plots differentially expressed genes HL-60 cells (B) molm13 (C) from the control palbociclib groups.</p>
<p>Table S1</p>
<p>Supplementary Figure Legends</p>
<p>Figure S3. Knockdown CDK4 and CDK6 via siRNA in HL-60 molm13 cells (A). The effect of palbociclib ATRA combination on cell cycle(B), proliferation (C), apoptosis (D). * Represent when it compares with the control group, P<0.05. # P<0.05.</p>
<p>Figure S1. The mutation frequency of CDK4/6-cyclin D pathway genes, CDKN1A and CDKN2A in 531 AML patients (A). expression was compared between healthy donors the BeatAML database. * Represent P<0.05.</p>
<p>Figure S1. The mutation frequency of CDK4/6-cyclin D pathway genes, CDKN1A and CDKN2A in 531 AML patients (A). expression was compared between healthy donors the BeatAML database. * Represent P<0.05.</p>
<p>Table S1</p>
<p>Supplementary Figure Legends</p>
<p>Figure S4. The effect of Palbociclib and ATRA combination on leukemia burden in vivo (A). Volcano plots differentially expressed genes HL-60 cells (B) molm13 (C) from the control palbociclib groups.</p>
<p>Figure S2. The comparison of the expression CDK4/6-cyclin D pathway genes based on age (A) and risk stratification (B). Kaplan-Meier curve for CDK6 (C). calibration nomogram 1-year 2-year overall survival (D).</p>